Atlas Trials

Recurrent Ependymoma

14 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Ependymoma

RecordFirmDate
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (NCT04743661)Pediatric Brain Tumor Consortium2022-04-04
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors (NCT04732065)Sabine Mueller, MD, PhD2021-08-23
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04320888)National Cancer Institute (NCI)2021-05-03
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04284774)National Cancer Institute (NCI)2020-10-13
Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Patients With Recurrent Posterior Fossa Ependymoma (NCT03572530)The University of Texas Health Science Center, Houston2019-02-08
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) (NCT03213652)National Cancer Institute (NCI)2018-04-17
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678)National Cancer Institute (NCI)2017-11-28
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665)National Cancer Institute (NCI)2017-11-13
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704)National Cancer Institute (NCI)2017-08-23
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620)National Cancer Institute (NCI)2017-07-31
Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors (NCT02271711)M.D. Anderson Cancer Center2015-03-17
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors (NCT00634231)Candel Therapeutics, Inc.2010-10-01

Track Recurrent Ependymoma automatically

Every clearance here is in the API, with alerts when new ones post.